PITTSBURGH, Feb. 26 Mylan Inc. (NYSE: MYL) todayannounced the appointment of Patrick Vink as Senior Vice President in the newposition of Global Head of Biologics. Mr. Vink will oversee Mylan's globalbiologics division and help develop the Company's strategy in this importantgrowth area.
Mr. Vink comes to Mylan with 20 years of experience in the globalpharmaceuticals industry including leadership roles at companies such asSanofi, Biogen and Sandoz. Most recently, he was as an independent consultantand advisor to life sciences companies, venture capital and private equityinvestors and non-governmental organizations (NGOs). Prior to becoming aconsultant, Mr. Vink served as the Global Head of Business UnitBiopharmaceuticals at Sandoz and as a member of Sandoz's Worldwide ExecutiveCommittee. In this position, he oversaw the technical and clinicaldevelopment, manufacturing and regulatory affairs for biopharmaceuticalproducts. In addition, he was responsible for manufacturing cooperation withother large biotech companies. Notably, while at Sandoz, Mr. Vink led thesuccessful development and registration of the first bio-similar (bio-generic)biopharmaceutical in the United States and Europe, a landmark event for thepharmaceutical industry.
Prior to joining Sandoz, Mr. Vink served as Vice President ofInternational Sales at Biogen and Associate Vice President, Cardiovascular-Thrombosis at Sanofi-Synthelabo.
Mylan Vice Chairman and CEO Robert J. Coury said, "As we have said forsome time, Mylan is committed to delivering an appropriate global biologicsstrategy and this remains one of our key remaining strategic imperatives.Patrick's strong reputation and significant experience in this specializedfield will be invaluable to this effort and ensure we are well-positioned inthis space at market formation. We are thrilled to welcome him to Mylan."
Mr. Vink said, "I am extremely pleased to be joining Mylan, particularlyat such an exciting time in the Company's development. I have been workingwith the Mylan team for some time as a consultant and have been very impressedwith their leadership and commitment to excellence in every area in which theyoperate. There are significant opportunities for Mylan in the global bio-generics area, given its reputation for manufacturing and operationalexcellence and high quality products. I am confident that my expertise in thebiologics field will produce a strong and competitive biologics platform forthe Company that leverages its global commercial footprint."
Mr. Vink earned his doctorate of medicine from the University of Leiden inthe Netherlands and an MBA from the William E. Simon School in Rochester, N.Y.He has also attended the Dutch Institute of Marketing in the Netherlands andpostgraduate courses at Harvard University and Stanford University.
Mylan Inc. is one of the world's leading quality generic and specialtypharmaceutical companies. The Company offers one of the industry's broadestand highest quality product portfolios, a robust product pipeline and a globalcommercial footprint through operations in more than 90 countries. Through itscontrolling interest in Matrix Laboratories Limited, Mylan has direct accessto one of the largest active pharmaceutical ingredient (API) manufacturers inthe world. Dey, L.P., Mylan's fully integrated specialty business, providesthe Company with innovative and diversified opportunities in the respiratoryand allergy therapeutic areas. For more information about Mylan, please visitwww.mylan.com.
SOURCE Mylan Laboratories Inc.